改善腸道菌群

羅伊氏乳酸桿菌DSM 17938與病原體競爭腸道粘附點(1)

寶乖亞 - 改善腸道菌群 - 羅伊氏乳酸桿菌 DSM 17938 功能 2

羅伊氏乳酸桿菌DSM 17938可生產抗微生物物質, 例如(2, 3)

  • 乳酸 (Lactic acid): 乳酸可降低腸道的pH值, 有利提供了乳酸桿菌 (lactobailli) 和雙歧桿菌 (bifidobacteria) 更好的生長的環境。
  • 乙酸 (Acetic acid): 乙酸除了具有降低pH值的作用外, 還對許多病原體具有抗菌作用。
  • 羅伊氏素 (Reuterin): 羅伊氏乳酸桿菌DSM 17938將甘油轉化為羅伊氏素, 從而引起氧化應激並抑制病原體（細菌,  病毒,  真菌）的生長
寶乖亞 - 改善腸道菌群 - 羅伊氏乳酸桿菌 DSM 17938 功能 4
寶乖亞 - 改善腸道菌群 - 羅伊氏乳酸桿菌 DSM 17938 功能 3

羅伊氏乳酸桿菌DSM 17938通過生產羅伊氏菌素, 乳酸和乙酸來抑制以下的病原體 (4-12)

寶乖亞 - 改善腸道菌群 - 羅伊氏乳酸桿菌 DSM 17938 功能 5

羅伊氏乳酸桿菌DSM 17938促進益生菌的生長, 改善剖腹產嬰兒的腸道菌群和自然產嬰兒腸道菌群相似(13)

寶乖亞 - 改善腸道菌群 - 羅伊氏乳酸桿菌 DSM 17938 功能 6
Google 羅伊氏乳酸桿菌DSM 17938

羅伊氏乳酸桿菌DSM17938改善健康

繼續閱讀

drug, pills, encapsulate

抗生素引起的腹瀉

抗生素引起的腹瀉是抗生素使用最常見的副作用。

ethics, right, wrong

益生菌錯誤觀念

1.益生菌都一樣啦 2.乳酸菌=益生菌 3.菌種越多越好 4.菌種越多越好…..

寶乖亞 - 羅伊氏乳酸桿菌DSM17938功能 - 改善免疫反應

羅伊氏乳酸桿菌DSM17938功能

改善免疫反應

參考

  1. Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G. (2007) Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol 12 Nov 2007 7(1):101.

  2. Axelsson L. Lactic acid bacteria: Classification and Physiology. In: Salminen S, von Wright A, eds. Lactic acid bacteria: microbiology and functional aspects. 2nd ed. New York: Marcel Dekker, 1998: 1–72.

  3. Schaefer et al (2010) The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. Microbiology 156:1589-1599.

  4. El-Ziney MG et al (2000) Reuterin. In Natural Food Antimicrobial Systems, Ed. Naidu AS, CRC Pres

  5. Ejehorn M. (2000) Presence of Lactobacillus ssp. in the human stomach and their effects on Helicobacter pylori. Diploma thesis, Engineering Programs, Uppsala University, Sweden.

  6. Caglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S. (2006) Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium

  7. Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odontol Scand 64:314-318.

  8. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. (2008) Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:166-171.

  9. Rosander A, Connolly E, Roos S. (2008) Removal of antibiotic resistance plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain L. reuteri DSM 17938. Appl Environ Microbiol. 74:6032-6040.

  10. Hedberg M, Karched M, Asikainen SEA. (2006, abstr.) In-vitro growth inhibition of periodontitis-associated species by Lactobacillus reuteri. Presented at Anaerobe 2006, the 8th Biennial Congress of the Anaerobe Society of the Americas, 25-28 July, Boise, ID, USA.

  11. Mikkonen T et al. (2001) No title. Finnish biopsy study on human subjects, verifying the ability of L.reuteri ATCC 55730 to colonize all parts of the colon. Reports about two subjects who were colonizedwith Klebsiella species before start of L. reuteri intake. Klebsiella disappeared completely during the trial period. BioGaia internal report.

  12. Shornikova A V, Casas lA, Mykkanen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis 1 1997; 16: 1103-7. 

  13. Garcia Rodenas CL, Lepage M, Ngom-Bru C, Fotiou A, Papagaroufalis K, Berger B. Effect of Formula Containing Lactobacillus reuteri DSM 17938 on Fecal Microbiota of Infants Born by Cesarean-Section. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):681-687.